The Nordic DeltaCon Trial for Displaced Proximal Humeral Fractures in Elderly
DeltaCon
Nordic DeltaCon Trial: Non-operative Treatment Versus Reversed Total Shoulder Prosthesis in Patients Sixty Five Years of Age and Older With Displaced 3- and 4 Parts Proximal Humeral Fractures - a Prospective, Randomized Controlled Trial
1 other identifier
interventional
154
3 countries
3
Brief Summary
The Nordic DeltaCon Trial is a prospective, single-blinded, randomized, controlled, multi-center and multi-national trial comparing reverse prosthesis and non-operative treatment in displaced proximal humerus fractures, in the elderly patients aged 65 to 85 years with displaced OTA/AO group B2 or C2 fractures (According to the new 2018 revision: AO/OTA (Orthopaedic Trauma Association) group 11-B1.1, 11-B1.2 and 11-C1.1, 11-C3.1. )
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Oct 2018
Longer than P75 for not_applicable
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 27, 2018
CompletedFirst Posted
Study publicly available on registry
May 21, 2018
CompletedStudy Start
First participant enrolled
October 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 10, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 10, 2028
ExpectedJanuary 6, 2026
December 1, 2025
5.2 years
April 27, 2018
December 31, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Quick-DASH
The short form of Disabilities of the arm, shoulder and hand
From enrollment to 5 years follow-up. Scale 1-4 points (Total point x answers given) x25. Lowest point best
Secondary Outcomes (6)
Oxford Shoulder Score
From enrollment to 5 years follow-up. Scale 0 - 48, lowest score best.
15 D Quality of Life
From enrollemtn to 5 years follow-up. 15 questions, 5 levels, scale 0.000 - 1.000. Highest number best.
Constant score (CS)
From enrollment to 5 years follow-up. Scale 0- 100 points. Highest best if only actual shoulder is scored..
VAS pain
From enrollement to 5 eyars follow-up. Scale 0-15 points, best equal zero points
Radiographic + Computer Tomography scan (CT)
From enrollemnt to 5 years follow-up for plain radiographs. CT at enrollement and at 2 years.
- +1 more secondary outcomes
Study Arms (2)
Operative treatment
ACTIVE COMPARATOROperative treatment of the displaced proximal humeral fracture with a reversed total shoulder prothesis (Delta prosthesis) using a stadardized deltopectoral approach, bone block grafting and thread cerclages of the tubercles. Rehabilitation with standardized physiotherapy guideline and self exercise protocol
Non-Operative treatment
NO INTERVENTIONRehabilitation with standardized physiotherapy guideline and self exercise protocol
Interventions
The standardized approach is the delto-pectoral to minimize any damage of the deltoid muscle. A cemented monoblock humeral stem will be implanted. Braided polyester suture-cerclages engaging the insertion of the subscapular and infraspinatus tendons enforced by a bonegraft or a "horseshoe-graft" from the humeral head will be used
Eligibility Criteria
You may qualify if:
- Low energy AO/OTA group 11-B1.1, 11-B1.2 and 11-C1.1, 11-C3.1. Both B and C type includes subgroups: Displaced \[2\], Impacted \[3\] or Non impacted \[4\] from the universal modifiers list.
You may not qualify if:
- Radiographic Mal-inclination Less than; varus 30°or valgus 45° Less than 50% contact between head fragment and meta-/diaphysis Head split fractures with more than 10% of the articular surface in the main head fragment.
- Head split fractures (group 11-C3.2 and 11-C3.3) with more than 10% of the articular surface in the main head fragment.
- Dislocation or fracture-dislocation of the gleno-humeral joint Pathological fracture
- General
- Refuse to participate
- Age under 65 years of age, or over 85 years of age
- Serious poly-trauma or additional surgery
- Non-independent, drug/alcohol abuse or institutionalized (low co-operation)
- Contra-indications for surgery
- Does not understand written and spoken guidance in local languages
- Previous fracture with symptomatic sequelae in either shoulder
- Patients living outside the hospital's catchment area
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Oslo University Hospitallead
- Tampere University Hospitalcollaborator
Study Sites (3)
Aarhus University Hospital, Division of Orthopaedics
Aarhus, Denmark
Tampere University Hospital, Division of Orthopaedics
Tampere, Finland
Oslo University Hospital, Division of Orthopaedics
Oslo, Norway
Related Publications (1)
Launonen AP, Fjalestad T, Laitinen MK, Lahdeoja T, Ekholm C, Wagle T, Mattila VM; NITEP-group. Nordic Innovative Trials to Evaluate osteoPorotic Fractures (NITEP) Collaboration: The Nordic DeltaCon Trial protocol-non-operative treatment versus reversed total shoulder arthroplasty in patients 65 years of age and older with a displaced proximal humerus fracture: a prospective, randomised controlled trial. BMJ Open. 2019 Jan 29;9(1):e024916. doi: 10.1136/bmjopen-2018-024916.
PMID: 30700485BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Ville Mattila, Professor
Professor in orthopedics and traumatology, Tampere University Chief of musculoskeletal department, Tampere University Hospital Visiting professor, Karolinska Institute, Stockholm
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- Physiotheraphists specialized in shoulder injuries collect all data and perform all tests / interviews of patients during FU at 3 months, 1-2-5 years. Blinded for the allocation / treatment.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator Tore Fjalestad, MD. Ph.D. Consultant Orthopaedic Surgeon, Mail: torfja@online.no / tofjal@ous-hf.no , Ph:+4797013389
Study Record Dates
First Submitted
April 27, 2018
First Posted
May 21, 2018
Study Start
October 1, 2018
Primary Completion
December 10, 2023
Study Completion (Estimated)
December 10, 2028
Last Updated
January 6, 2026
Record last verified: 2025-12